Aadi Bioscience
Aadi Bioscience develops precision medicines for rare cancers driven by genomic alterations, with their leading asset FYARRO® targeting mTOR pathway activation in specific cancers.
Company Overview
Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision medicines for rare cancers driven by genomic alterations. Headquartered in Pacific Palisades, California, and with an additional office in Morristown, New Jersey, the company leverages albumin-bound nanoparticle technology to advance their investigational drug candidates. Aadi Bioscience is committed to creating a diverse and inclusive workplace and has grown to more than 80 employees since its public listing.
Products
Aadi Bioscience's leading product, FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension), targets cancers driven by mTOR pathway activation. FYARRO® has received approval in the United States for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). The company also explores the broader applications of nab-sirolimus for patients with malignant solid tumors harboring inactivating alterations in TSC1 or TSC2 genes.
Clinical Trials
Aadi Bioscience is leading the PRECISION 1 trial, a phase 2, open-label, tumor-agnostic, multicenter basket trial of nab-sirolimus. The PRECISION 1 study targets patients aged 12 years or older with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes. The primary objective is to determine the overall response rate (ORR) in these patients until disease progression. Additionally, the company has launched a new clinical collaboration to explore the combination of nab-sirolimus with a KRAS inhibitor in NSCLC and other cancers.
Funding and Growth
Aadi Bioscience raised $155 million in conjunction with its public listing in August 2021. The company secured an additional $72.5 million in financing in September 2022 to support their new clinical collaboration. Since its public listing, Aadi Bioscience has expanded to more than 80 employees and continues to invest in research and development to advance their mission.
Strategic Collaborations
To optimize their clinical studies and increase study awareness within the community, Aadi Bioscience has engaged with multiple advocacy and research groups across the sarcoma landscape. Their collaborations aim to enhance the design and implementation of clinical trials, ensuring that patients benefit from cutting-edge precision medicine research.